AstraZeneca (NYSE:AZN) announced that it entered into a definitive agreement to acquire Alexion Pharmaceuticals (NSDQ:ALXN), expanding its presence in the rare-disease and immunology drugs space.
The acquisition price for Boston-based Alexion is set to total approximately $39 billion, or $175 per share, according to a news release.
Get the full story at our sister site, Drug Discovery & Development.